The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease-Reference-Cited by-同舟云学术

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease

Published:2020-08-18 Issue: Volume:14 Page:
ISSN:1662-453X
Container-title:Frontiers in Neuroscience
language:
Short-container-title:Front. Neurosci.

Author:

Rideout Hardy J.,Chartier-Harlin Marie-Christine,Fell Matthew J.,Hirst Warren D.,Huntwork-Rodriguez Sarah,Leyns Cheryl E. G.,Mabrouk Omar S.,Taymans Jean-Marc

Publisher

Frontiers Media SA

Subject

General Neuroscience

Reference109 articles.

1. Higher Urine bis(Monoacylglycerol)phosphate levels in LRRK2 G2019S mutation carriers: implications for therapeutic development.;Alcalay;Mov. Disord.,2019

2. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations.;Alcalay;Brain,2015

3. LRRK2 kinase in Parkinson’s disease.;Alessi;Science,2018

4. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by Anti-peptide antibodies (SISCAPA).;Anderson;J. Proteome Res.,2004

5. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson’s disease patients.;Atashrazm;Mov. Disord.,2018

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors;Journal of Medicinal Chemistry;2024-09-04

2. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date;Expert Opinion on Therapeutic Patents;2024-07-19

3. Regulation of Leucine-Rich Repeat Kinase 2 by inflammation and IL-4;2024-05-02

4. GBA1-and LRRK2-directed Treatments: The Way Forward;Parkinsonism & Related Disorders;2024-05

5. Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson’s Disease;Journal of Parkinson's Disease;2024-04-23